BioSpace

BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.

Por BioSpace

1 minuto de lectura
Compartir
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas